Drugs / WS-CART-CS1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06185751 | Aug 2024 → Aug 2029 expected | plasma cell myeloma | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WS-CART-CS1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06185751 ↗ |
| Modality | Cell therapy | “WS-CART-CS1, a CAR-T cell therapy targeting CS1.” NCT06185751 ↗ |
| Target | SLAMF7 | “CS1(SLAMF7)-targeting CAR-T cells” NCT06185751 ↗ |